Merrimack Pharmaceuticals, Inc. (MACK)

Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure

Merrimack Pharmaceuticals Inc's (NASDAQ: MACK) partner announced that Ipsen SA (OTC: IPSEY) reported a primary analysis of the results of the Phase 3 trial of Onivyde (irinotecan liposomal injection)for second-line small cell lung cancer (SCLC). The study did not meet the primary endpoint of overall survival in patients treated with Onivyde versus topotecan. However, a doubling of the secondary endpoint of objective response rate (ORR) in favor of Onivyde was observed. The safety and tolerabilit